阿帕替尼与替吉奥二线治疗晚期胃癌患者的临床疗效比较

目的 探究阿帕替尼与替吉奥二线治疗晚期胃癌患者的临床疗效.方法 选取经化学药物治疗失败的晚期胃癌患者118例,依据治疗方案的不同将患者分为靶向组及对照组,各59例,其中,靶向组患者口服阿帕替尼进行治疗,对照组患者口服替吉奥进行治疗;观察比较两组患者治疗前及治疗过程中白细胞计数(WBC)、血小板计数(PLT)、不良反应情况及疗效.结果 治疗前两组患者的WBC及PLT比较,差异无统计学意义(P﹥0.05);治疗过程中靶向组患者腹泻、皮疹及口腔炎的发生率低于对照组,高血压及手足综合征的发生率高于对照组,差异有统计学意义(P﹤0.05);治疗后两组患者的WBC及PLT水平均降低,且对照组患者降低更为显著(P﹤0.05);靶向组患者的疗效优于对照组,差异有统计学意义(P﹤0.05).结论 靶向药物阿帕替尼相对于替吉奥对二线治疗晚期胃癌患者具有疗效显著、不良反应轻微等优势;治疗过程中靶向组出现较多的血压升高患者,经对症治疗后症状得到缓解.

The clinical effect comparison between apatinib and S-1 as the second-line treatment for advanced gastric cancer

Objective To compare the clinical effect of apatinib or tegafur/gimeracil/oteracil (S-1) as the second-line treatment for advanced gastric cancer. Method 118 patients with advanced gastric cancer who failed chemotherapy were enrolled in this study. The patients were stratified as targeted therapy group or control group according to respective treat-ment, with 59 cases in each. The patients in the targeted therapy group were treated with oral apatinib and the control group were given S-1. The white blood cell (WBC), platelet count (PLT), adverse events and therapeutic effect of the two groups were observed before and after treatment. Result There was no significant differences in WBC and PLT between the two groups before treatment (P>0.05). The number of patients with diarrhea, rash and stomatitis in targeted therapy group was less than those of control group, while the incidence of hypertension and hand-foot syndrome was higher than that of the control group, and the difference was statistically significant (P<0.05). WBC and PLT in both groups were de-creased after treatment, and greater reduction was observed in control group as compared with targeted therapy group (P<0.05). The therapeutic effect was significantly better in targeted therapy group than in control group (P<0.05). Conclusion Apatinib, the targeted drug, is therapeutically effective in the treatment of patients with advanced gastric cancer, as com-pared with S-1 as the second-line therapy, with mild adverse effects;the higher incidence of hypertension induced by apa-tinib may be reduced by symptomatic treatment.